Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals (Nasdaq: IONS), has announced that the pivotal Phase III APPROACH study of volanesorsen met its primary endpoint of reducing triglyceride levels in patients with familial chylomicronemia syndrome (FCS).
Rather than the US biotech’s share price rising after the results were announced on Tuesday, however, it had dropped nearly 6% by lunchtime to $47.01.
The reason for this reaction from investors has been linked to the safety data that was published, with five volanesorsen-treated patients in the trial having their treatment discontinued due to platelet-related adverse events, a finding which will have reminded investors of Ionis’ experience last year with another antisense drug, IONIS-TTR.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze